aprocitentan - PMC

Result Filters

You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 1 to 20 of 75

<< First< Prev

Page of 4

Next >Last >>

Select item 79843231.

Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet

Pierre Gueneau de Mussy, Patricia N. Sidharta, Gregoire Wuerzner, Marc P. Maillard, Nicolas Guérard, Marc Iglarz, Bruno Flamion, Jasper Dingemanse, Michel Burnier

Clin Pharmacol Ther. 2021 Mar; 109(3): 746–753. Published online 2020 Sep 29. doi: 10.1002/cpt.2043

PMCID:: PMC7984323

Abstract Article PDF–453K

Select item 64351202.

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects

Patricia N Sidharta, Meggane Melchior, Martin K Kankam, Jasper Dingemanse

Drug Des Devel Ther. 2019; 13: 949–964. Published online 2019 Mar 22. doi: 10.2147/DDDT.S199051

PMCID:: PMC6435120

Abstract Article PDF–1010K

Select item 96453403.

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

Magda S. C. Fontes, Jasper Dingemanse, Atef Halabi, Monika Tomaszewska-Kiecana, Patricia N. Sidharta

Sci Rep. 2022; 12: 19067. Published online 2022 Nov 9. doi: 10.1038/s41598-022-22470-z

PMCID:: PMC9645340

Abstract Article PDF–1001K

Select item 103393694.

Aprocitentan: A new development of resistant hypertension

Yao Yao, Bin Fan, Bin Yang, Zixuan Jia, Bao Li

J Clin Hypertens (Greenwich) 2023 Jul; 25(7): 587–590. Published online 2023 Jun 19. doi: 10.1111/jch.14686

PMCID:: PMC10339369

Abstract Article PDF–163K

Select item 70984345.

Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension

Pierre Verweij, Parisa Danaietash, Bruno Flamion, Joël Ménard, Marc Bellet

Hypertension. 2020 Apr; 75(4): 956–965. Published online 2020 Feb 17. doi: 10.1161/HYPERTENSIONAHA.119.14504

PMCID:: PMC7098434

Abstract Article PDF–475K

Select item 92785946.

Identifying and treating resistant hypertension in PRECISION: A randomized long‐term clinical trial with aprocitentan

Parisa Danaietash, Pierre Verweij, Ji‐Guang Wang, George Dresser, Ilkka Kantola, Mary Katherine Lawrence, Krzysztof Narkiewicz, Markus Schlaich, Marc Bellet, the PRECISION investigators

J Clin Hypertens (Greenwich) 2022 Jul; 24(7): 804–813. Published online 2022 Jun 9. doi: 10.1111/jch.14517

PMCID:: PMC9278594

Abstract Article PDF–1.2M

Select item 105051057.

Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension

Sayeh Heidari Nejad, Omar Azzam, Markus P. Schlaich

Curr Hypertens Rep. 2023; 25(10): 343–352. Published online 2023 Aug 11. doi: 10.1007/s11906-023-01259-z

PMCID:: PMC10505105

Abstract Article PDF–1.9M

Select item 85550378.

Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension

Fabio Angeli, Paolo Verdecchia, Gianpaolo Reboldi

Cardiol Ther. 2021 Dec; 10(2): 397–406. Published online 2021 Jul 12. doi: 10.1007/s40119-021-00233-7

PMCID:: PMC8555037

Abstract Article PDF–307K

Select item 32820109.

Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist

Shirin Bruderer, Päivi Äänismaa, Marie-Claude Homery, Stephanie Häusler, Kyle Landskroner, Patricia N. Sidharta, Alexander Treiber, Jasper Dingemanse

AAPS J. 2012 Mar; 14(1): 68–78. Published online 2011 Dec 22. doi: 10.1208/s12248-011-9316-3

PMCID:: PMC3282010

Abstract Article PDF–479K

Select item 1005175610.

Novel Dual Endothelin Inhibitors in the Management of Resistant Hypertension

Chrysoula Boutari, Fotios Siskos

Life (Basel) 2023 Mar; 13(3): 806. Published online 2023 Mar 16. doi: 10.3390/life13030806

PMCID:: PMC10051756

Abstract Article PDF–832K

Select item 1110312511.

Bioequivalence and the food effect of macitentan/tadalafil 10/20 fixed‐dose combination tablets versus the use of single‐component tablets in healthy subjects

Jennifer Lynn Ford, Ahad Sabet, Jaya Natarajan, Hans Stieltjes, Daniel L. Chao, Navin Goyal, Denes Csonka

Pharmacol Res Perspect. 2024 Jun; 12(3): e1202. Published online 2024 May 19. doi: 10.1002/prp2.1202

PMCID:: PMC11103125

Abstract Article PDF–2.2M

Select item 981374012.

Aprocitentan: New insights

Fahimeh Varzideh, Urna Kansakar, Stanislovas S. Jankauskas, Gaetano Santulli

Front Cardiovasc Med. 2022; 9: 1093406. Published online 2022 Dec 22. doi: 10.3389/fcvm.2022.1093406

PMCID:: PMC9813740

Article PDF–756K

Select item 1076877713.

New trials in resistant hypertension: mixed blessing stories

Carmine Zoccali, Francesca Mallamaci, Luca De Nicola, Roberto Minutolo

Clin Kidney J. 2024 Jan; 17(1): sfad251. Published online 2023 Sep 27. doi: 10.1093/ckj/sfad251

PMCID:: PMC10768777

Abstract Article PDF–1.6M

Select item 1068914014.

Hypertension in chronic kidney disease—treatment standard 2023

Panagiotis I Georgianos, Rajiv Agarwal

Nephrol Dial Transplant. 2023 Dec; 38(12): 2694–2703. Published online 2023 Jun 24. doi: 10.1093/ndt/gfad118

PMCID:: PMC10689140

Abstract Article PDF–724K

Select item 1104310615.

Systematic Review Article: New Drug Strategies for Treating Resistant Hypertension—the Importance of a Mechanistic, Personalized Approach

Giulia Nardoianni, Barbara Pala, Alessandra Scoccia, Massimo Volpe, Emanuele Barbato, Giuliano Tocci

High Blood Press Cardiovasc Prev. 2024; 31(2): 99–112. Published online 2024 Apr 14. doi: 10.1007/s40292-024-00634-4

PMCID:: PMC11043106

Abstract Article PDF–960K

Select item 850034316.

Bioequivalence and food effect of a fixed‐dose combination of macitentan and tadalafil: Adaptive design in the COVID‐19 pandemic

Dénes Csonka, Vladislav Fishman, Jaya Natarajan, Hans Stieltjes, Danielle Armas, Victor Dishy, Juan Jose Perez Ruixo

Pharmacol Res Perspect. 2021 Oct; 9(5): e00846. Published online 2021 Oct 8. doi: 10.1002/prp2.846

PMCID:: PMC8500343

Abstract Article PDF–746K

Select item 1147807117.

Arterial Hypertension: Novel Pharmacological Targets and Future Perspectives

Irene Paula Popa, Andreea Clim, Alin Constantin Pînzariu, Cristina Iuliana Lazăr, Ștefan Popa, Ivona Maria Tudorancea, Mihaela Moscalu, Dragomir N. Șerban, Ionela Lăcrămioara Șerban, Irina-Iuliana Costache-Enache, Ionuț Tudorancea

J Clin Med. 2024 Oct; 13(19): 5927. Published online 2024 Oct 4. doi: 10.3390/jcm13195927

PMCID:: PMC11478071

Abstract Article PDF–2.9M

Select item 625599218.

Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided

Andrea Huppertz, Lars Werntz, Andreas D. Meid, Kathrin I. Foerster, Jürgen Burhenne, David Czock, Gerd Mikus, Walter E. Haefeli

Br J Clin Pharmacol. 2018 Dec; 84(12): 2903–2913. Published online 2018 Oct 11. doi: 10.1111/bcp.13757

PMCID:: PMC6255992

Abstract Article PDF–467K

Select item 1123181719.

The Global Burden of Resistant Hypertension and Potential Treatment Options

Giacomo Buso, Claudia Agabiti-Rosei, Matteo Lemoli, Federica Corvini, Maria Lorenza Muiesan

Eur Cardiol. 2024; 19: e07. Published online 2024 Jun 19. doi: 10.15420/ecr.2023.51

PMCID:: PMC11231817

Abstract Article PDF–907K

Select item 1010062520.

Advances in Clinical Cardiology 2022: A Summary of Key Clinical Trials

Patrick Savage, Brian Cox, Michael Shahmohammadi, Johnathan Foster, Ian Menown

Adv Ther. 2023; 40(6): 2595–2625. Published online 2023 Apr 13. doi: 10.1007/s12325-023-02502-4

PMCID:: PMC10100625

Abstract Article PDF–1.9M

<< First< Prev

Page of 4

Next >Last >>

Supplemental Content

Filter your results:

All (75)
NIH grants (6)
Embargoed (0)

Manage Filters

PMC Images search for aprocitentan

FIGURE 1

Chemical structure of aprocitentan.

Aprocitentan: A new development of resistant hypertension

J Clin Hypertens (Greenwich). 2023 Jul;25(7):587-590.
Fig. 1

Chemical structure of aprocitentan

Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension

Cardiol Ther. 2021 Dec;10(2):397-406.
Figure 1

Structure of aprocitentan and schematic representation of the three parts of the PRECISION trial.

Aprocitentan: New insights

Front Cardiovasc Med. 2022;9:1093406.
Figure 4

Arithmetic mean (±SD) plasma concentration following the last dose administration on Day 10 (A) and mean trough plasma concentration–time profiles (B) of aprocitentan after once-daily administration of multiple doses of aprocitentan to healthy subjects and 100 mg of aprocitentan to healthy elderly subjects (n=6 for 5, 25, and 100 mg elderly; n=5 in the 100 mg group).

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects

Drug Des Devel Ther. 2019;13:949-964.

See more (34)...

Find related data

Search details

Recent activity

Clear Turn Off Turn On

aprocitentan (75)
PMC
uncharacterized protein LOC120089288 [Benincasa hispida]
uncharacterized protein LOC120089288 [Benincasa hispida]
gi|1955827130|ref|XP_038902640.1|

Protein
rab escort protein 1 [Cucumis sativus]
rab escort protein 1 [Cucumis sativus]
gi|449456881|ref|XP_004146177.1|

Protein
60S ribosomal protein L10a [Cucurbita moschata]
60S ribosomal protein L10a [Cucurbita moschata]
gi|1279781754|ref|XP_022943718.1|

Protein
L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase isofor...
L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase isoform X1 [Cucumis sativus]
gi|449434500|ref|XP_004135034.1|

Protein

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

You are here: NCBI > Literature > PubMed Central (PMC)

Support Center

PMC

Result Filters

Article attributes

Text availability

Publication date

Custom date range

Research Funder

Additional filters

Display Settings:

Send to: